Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment
130
Participants
Timeline
Start Date
October 17, 2017
Primary Completion Date
June 7, 2022
Study Completion Date
June 7, 2022
Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
BIOLOGICAL
Trivalent Influenza Vaccine
Given IM
Trial Locations (1)
14263
Roswell Park Cancer Institute, Buffalo
All Listed Sponsors
lead
Roswell Park Cancer Institute
OTHER
NCT04484532 - Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers | Biotech Hunter | Biotech Hunter